People: Merck KGaA (MKGAY.PK)
53.55USD
23 May 2013
$0.73 (+1.38%)
$52.82
$53.48
$53.56
$53.03
1,715
4,400
$53.56
$29.92
Krebs, Rolf
Brief Biography
Prof. Dr. Rolf Krebs has been Chairman of the Supervisory Board at Merck KGaA since July 1, 2009. He has been Member of the Supervisory Board at Merck KGaA since July 1, 2006. He is retired Physician. He graduated from Johannes Gutenberg-Universitat Mainz with a Doctorate of Science degree in Medicine. He is Chairman of the Supervisory Board of Epigenomics AG and Ganymed Pharmaceuticals AG. He is Member of the Supervisory Board of Merz GmbH & Co. KGaA, Senator GmbH &Co KGaA and Merz Pharmaceuticals GmbH. He is on the Board of Partners at E. Merck KG and on the Board of Air Liquide S.A. He is Chairman of the Research and Development Committee, as well as Member of the Personnel Committee at the Company.
Basic Compensation
| Total Annual Compensation, EUR | Long-Term Incentive Plans, EUR | All Other, EUR | Fiscal Year Total, EUR |
|---|---|---|---|
| 79,318 | -- | -- | 79,318 |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
Rolf Krebs |
79,318 |
Karl-Ludwig Kley |
5,549,000 |
Heiner Wilhelm |
59,488 |
Matthias Zachert |
4,153,000 |
Kai Beckmann |
3,653,000 |
Constantin Fest |
-- |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
